Drug-eluting stents in patients with ESRD on dialysis: a small step forward.

摘要

Cardiovascular disorders represent the single most significant comorbid condition for patients with end-stage renal disease (ESRD) on dialysis therapy, leading to approximately 45% of deaths in this patient population. At the time of initiation of dialysis therapy, obstructive coronary artery disease (CAD) is present in greater than 50% of patients. One-year mortality after an acute myocardial infarction in this population is strikingly high (up to 60%). Despite these facts and the major advances in medical therapeutics and percutaneous and surgical revascularization for CAD during the last 2 decades, dialysis patients have been systematically excluded from clinical trials evaluating and establishing these advances